Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Nicotinate SCHEMBL502614 | 0.88 | L3MBTL1 (0.51) | ALDH1A1KMT2AL3MBTL1 | |
| Ribose (Furanose) SCHEMBL5520297 | 0.84 | ALDH1A1 (0.55) | ALDH1A1KMT2ATHRB | |
| Ribose (Furanose) SCHEMBL502577 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KMT2ATHRB | |
| Ribose (Furanose) SCHEMBL18185139 | 0.83 | F7 (0.59) | ALDH1A1THRB | |
| Ribose (Furanose) SCHEMBL14321532 | 0.83 | F7 (0.59) | ALDH1A1THRB | |
| Ribose (Furanose) SCHEMBL338518 | 0.83 | F7 (0.59) | ALDH1A1THRB | |
| Dextrose SCHEMBL28858708 | 0.83 | TSHR (0.54) | ALDH1A1 | |
| Ribose (Furanose) SCHEMBL502608 | 0.82 | TSHR (0.43) | ALDH1A1HSD17B10THRB | |
| Ribose (Furanose) SCHEMBL23111913 | 0.82 | F7 (0.58) | ALDH1A1THRB | |
| SCHEMBL25387949 | 0.81 | ALDH1A1 (0.46) | ALDH1A1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017218580-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF NICOTINAMIDE RIBOSIDE AND RELATED COMPOUNDS | REJUVENATION THERAPEUTICS CORPORATION (US) | 2017-12-21 | — | — | WO | claimed |
| WO-2017218580-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF NICOTINAMIDE RIBOSIDE AND RELATED COMPOUNDS | REJUVENATION THERAPEUTICS CORPORATION (US) | 2017-12-21 | — | — | WO | disclosed |
| US-9603862-B2 | Activation and activators of SIRT5 | CORNELL UNIVERSITY (US) | 2017-03-28 | — | — | US | disclosed |
| US-20120329748-A1 | ACTIVATION AND ACTIVATORS OF SIRT5 | CORNELL UNIVERSITY (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011081942-A1 | ACTIVATION AND ACTIVATORS OF SIRT5 | CORNELL UNIVERSITY (US) | 2011-07-07 | — | — | WO | disclosed |
| EP-1957086-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007061798-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329748-A1 | ACTIVATION AND ACTIVATORS OF SIRT5 | SIRT1, SIRT5, SIRT7 | ALDH1A1 2647/4885KMT2A 412/4885L3MBTL1 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.